Better Therapeutics Statistics
Total Valuation
Better Therapeutics has a market cap or net worth of 5,452. The enterprise value is 7.71 million.
| Market Cap | 5,452 |
| Enterprise Value | 7.71M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Better Therapeutics has 54.52 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 54.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +23.32% |
| Owned by Insiders (%) | 48.35% |
| Owned by Institutions (%) | 0.01% |
| Float | 28.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.24 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.30 |
Financial Position
The company has a current ratio of 0.57
| Current Ratio | 0.57 |
| Quick Ratio | 0.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.55 |
| Interest Coverage | -15.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -95.05% |
| Return on Capital (ROIC) | -140.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -584,685 |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.94% in the last 52 weeks. The beta is 1.92, so Better Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.92 |
| 52-Week Price Change | -99.94% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 48.98 |
| Average Volume (20 Days) | 81,882 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.61M |
| Pretax Income | -31.56M |
| Net Income | -31.57M |
| EBITDA | -29.18M |
| EBIT | -29.61M |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has 6.60 million in cash and 14.31 million in debt, giving a net cash position of -7.71 million or -0.14 per share.
| Cash & Cash Equivalents | 6.60M |
| Total Debt | 14.31M |
| Net Cash | -7.71M |
| Net Cash Per Share | -0.14 |
| Equity (Book Value) | -9.94M |
| Book Value Per Share | -0.24 |
| Working Capital | -5.59M |
Cash Flow
In the last 12 months, operating cash flow was -26.08 million and capital expenditures -45,000, giving a free cash flow of -26.13 million.
| Operating Cash Flow | -26.08M |
| Capital Expenditures | -45,000 |
| Free Cash Flow | -26.13M |
| FCF Per Share | -0.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Better Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.78% |
| Shareholder Yield | -29.78% |
| Earnings Yield | -1,076,898.00% |
| FCF Yield | -479,276.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |